- Home
- IBRX
IBRX
ImmunityBio Inc.
as 11-15-2024 4:00pm EST
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.4B | IPO Year: | N/A |
| Target Price: | $17.38 | AVG Volume (30 days): | 10.4M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.10 - $10.53 | Next Earning Date: | 11-12-2024 |
| Revenue: | $7,332,000 | Revenue Growth: | 1218.71% |
| Revenue Growth (this year): | 1563.18% | Revenue Growth (next year): | 1262.20% |
Latest ImmunityBio Inc. News
IBRX Breaking Stock News: Dive into IBRX Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
ImmunityBio Reports Third-Quarter 2024 Financial Results
GuruFocus.com
23 days ago
ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?
Business Wire
24 days ago
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
Business Wire
a month ago
ImmunityBio to Participate in the Jefferies London Healthcare Conference
Business Wire
2 months ago
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
Business Wire
3 months ago
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
Business Wire
3 months ago
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
Simply Wall St.
4 months ago
Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop
Compare IBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IBRX ImmunityBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.